Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Major study: Bioartificial liver reduces mortality by 44 percent in acute liver-failure patients

22.04.2004


In a major study conducted at 20 centers in the United States and Europe, a bioartificial liver developed by researchers at Cedars-Sinai Medical Center reduced mortality significantly among patients suffering from acute liver failure, the dramatic loss of liver function that can cause death in days or even hours. Study results are published in the May issue of Annals of Surgery.



This is the first large-scale, prospective, randomized, multi-center trial examining the effectiveness of any artificial liver support. Currently, standard treatment consists of intensive, supportive care intended to keep patients alive long enough that the liver might recover spontaneously or a donor organ will become available for transplantation.

Acute liver failure is diagnosed when a massive loss of hepatic cells causes severe liver dysfunction and life-threatening complications within six months of the onset of symptoms. When this dysfunction occurs within the first eight weeks after onset, liver failure is termed "fulminant." When it occurs in the period between eight weeks and six months, it is "subfulminant" (or late-onset). In either case, few patients survive the resulting fluid buildup in the brain, catastrophic bacterial infections, multi-organ failure, blood-clotting abnormalities, respiratory problems, kidney failure or other potential complications. It is estimated, in fact, that up to 80 percent of patients will die unless they receive a liver transplant.


In the United States, the causes of many cases of acute liver failure are never identified, although precipitating factors can include toxic poisoning, medication interactions or overdoses, metabolic disorders, and some types of viral hepatitis.

Achilles A. Demetriou, MD, PhD, Chairman of Surgery at Cedars-Sinai and the study’s principal investigator, has been pursuing treatments for acute liver diseases since 1976 when he began studying liver cells at the National Institutes of Health. He continued his research at Vanderbilt University, coming to Cedars-Sinai in 1992 to launch the country’s first unit devoted to managing massive acute liver failure.

The study included 147 patients who suffered from fulminant/subfulminant hepatic failure and 24 patients whose livers had failed after transplantation. Of the 171 total patients, 85 received BAL treatment, while 86 received standard supportive care.

For the entire patient population, survival at 30 days was 71 percent among the BAL group, compared with 62 percent for those receiving traditional care. Analyzing results among only the 147 patients with fulminant/subfulminant hepatic failure, the researchers found that the BAL provided a 44 percent reduction in mortality.

During a treatment, blood is drawn from a vein through a catheter. Blood plasma is separated from the serum and pumped through a charcoal column and an oxygenator before it reaches the bioreactor – a tube-shaped device containing a fiber membrane and 7 billion liver cells from pigs. These cells are isolated, cryopreserved (frozen) and thawed according to techniques originally developed by the Cedars-Sinai researchers.

"The blood is removed at a fixed rate, detoxified and treated in the various components of the bioartificial liver, reconstituted, and returned to the patient at the same rate at which it is being removed," said Dr. Demetriou. "Just before the patient is treated, the pig liver cells are thawed, reactivated and attached to small beads that serve as a scaffold for the cells. We put the cells and beads into the cartridge, and when the patient’s plasma flows through the fibers, the pig liver cells detoxify it and replace missing nutrients."

Each treatment is completed in about six hours, and the benefits last about 24 hours. In most cases of acute liver failure, a series of treatments may need to continue for only a few days or several weeks. "Typically, within that time the patient’s condition is going to improve because his or her own liver kicks in or a liver will be available for transplantation," Dr. Demetriou said.


The study was funded by Circe Biomedical Inc.

Cedars-Sinai is one of the largest nonprofit academic medical centers in the Western United States. For the fifth straight two-year period, it has been named Southern California’s gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. The Medical Center ranks among the top 10 non-university hospitals in the nation for its research activities.

Sandra Van | Van Communications
Further information:
http://www.csmc.edu/

More articles from Health and Medicine:

nachricht Finding new clues to brain cancer treatment
21.02.2020 | Case Western Reserve University

nachricht UIC researchers find unique organ-specific signature profiles for blood vessel cells
18.02.2020 | University of Illinois at Chicago

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A step towards controlling spin-dependent petahertz electronics by material defects

The operational speed of semiconductors in various electronic and optoelectronic devices is limited to several gigahertz (a billion oscillations per second). This constrains the upper limit of the operational speed of computing. Now researchers from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg, Germany, and the Indian Institute of Technology in Bombay have explained how these processes can be sped up through the use of light waves and defected solid materials.

Light waves perform several hundred trillion oscillations per second. Hence, it is natural to envision employing light oscillations to drive the electronic...

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

Im Focus: Skyrmions like it hot: Spin structures are controllable even at high temperatures

Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices

The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...

Im Focus: Making the internet more energy efficient through systemic optimization

Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.

Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.

Im Focus: New synthesis methods enhance 3D chemical space for drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.

"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

NUI Galway highlights reproductive flexibility in hydractinia, a Galway bay jellyfish

24.02.2020 | Life Sciences

KIST researchers develop high-capacity EV battery materials that double driving range

24.02.2020 | Materials Sciences

How earthquakes deform gravity

24.02.2020 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>